Direct and Indirect Costs of Influenza-Like Illness Treated with and Without Oseltamivir in 15 European Countries:A Descriptive Analysis Alongside the Randomised Controlled ALIC(4)E Trial

Autor: Nick A Francis, Christopher C Butler, Philippe Beutels, Réka Mikó-Pauer, Ana García-Sangenís, Nikolaos Tsakountakis, Pär-Daniel Sundvall, Katarzyna Kosiek, Joke Bilcke, Rune Aabenhus, Emily Bongard, Ruta Radzeviciene Jurgute, Nicolay Jonassen Harbin, Samuel Coenen, Alike W van der Velden, Xiao Li, Bohumil Seifert, Pascale Bruno, Robin Bruyndonckx, Dominik Glinz

Publikováno v: Li, X, Bilcke, J, van der Velden, A W, Bongard, E, Bruyndonckx, R, Sundvall, P-D, Harbin, N J, Coenen, S, Francis, N, Bruno, P, Garcia-Sangenis, A, Glinz, D, Kosiek, K, Miko-Pauer, R, Radzeviciene Jurgute, R, Seifert, B, Tsakountakis, N, Aabenhus, R, Butler, C C & Beutels, P 2021, ' Direct and Indirect Costs of Influenza-Like Illness Treated with and Without Oseltamivir in 15 European Countries : A Descriptive Analysis Alongside the Randomised Controlled ALIC(4)E Trial ', Clinical Drug Investigation, vol. 41, pp. 685–699 . https://doi.org/10.1007/s40261-021-01057-y
Clinical Drug Investigation
Clinical drug investigation

Background and Objective Influenza-like illness (ILI) leads to a substantial disease burden every winter in Europe; however, oseltamivir is not frequently prescribed to ILI patients in the primary-care setting. An open-label, multi-country, multi-sea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a5373c91ce16eb40ed34701294b3678
https://curis.ku.dk/ws/files/276160160/Direct_and_Indirect_Costs_of_Influenza_Like_Illness_Treated_with_and_Without_Oseltamivir_in_15_European_Countries.pdf